Us­ing her­pes virus vec­tors, Paul Pe­ter Tak and Carl June team up to solve the CAR-T sol­id tu­mor chal­lenge

Paul Pe­ter Tak’s on­colyt­ic virus start­up is jump­ing head-first in­to a new part­ner­ship, look­ing to tack­le sol­id tu­mor CAR-Ts.

Can­del Ther­a­peu­tics is join­ing forces with Carl June’s lab at the Uni­ver­si­ty of Penn­syl­va­nia to see if the her­pes virus can boost the ef­fec­tive­ness of CAR-T ther­a­pies in sol­id tu­mors, the biotech an­nounced Wednes­day morn­ing. No fi­nan­cial terms were dis­closed, and both par­ties will re­tain their re­spec­tive in­tel­lec­tu­al prop­er­ty rights.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER